June 2019 - Volume 3 - Issue S1 - Contributor Index

Author:
Vaccaro, E.
Author:
Vaclavu, L.
Author:
Vaddi, K.

PS1037 FINAL REPORT: CLINICAL STUDY OF ORAL ARSENIC TRIOXIDE CAPSULE FORMULATION, ORH-2014, DEMONSTRATING HIGH BIOAVAILABILITY, GOOD SAFETY AND TOLERABILITY IN PATIENTS WITH ADVANCED HEMATOLOGIC DISORDERS

Ravandi, F.; Tallman, M.; Roboz, G.; More

HemaSphere. 3(S1):468-469, June 2019.

Author:
Vadher, B.

PF691 SPLENECTOMY IN IMMUNE THROMBOCYTOPENIA: DO CHANGING TREATMENT PATTERNS FOR ITP AFFECT OUTCOMES? DATA FROM THE UK ITP REGISTRY

Todd, S.; Infirri, S. Sardo; Miah, H.; More

HemaSphere. 3(S1):299-300, June 2019.

Author:
Vadikolia, C.

PF191 RECLASSIFICATION OF BIPHENOTYPIC ACUTE LEUKEMIA INTO MIXED-PHENOTYPE ACUTE LEUKEMIA ACCORDING TO WHO CRITERIA REFINES PATIENT CHARACTERIZATION AND PROGNOSIS; DISEASE MARKERS AND IMPACT ON OUTCOME

Douka, V.; Kotta, K.; Chatziioannidis, A.; More

HemaSphere. 3(S1):47-48, June 2019.

Author:
Vaes, M.

PF694 TREATMENT-FREE REMISSION AFTER TPO RECEPTOR AGONISTS IN ADULT ITP PATIENTS IN BELGIUM

Janssens, A.; Beguin, Y.; Lambert, C.; More

HemaSphere. 3(S1):301, June 2019.

Author:
VAGDATLI, E.
Author:
Vago, E.
Author:
Vago, L.

PS1061 ELDERLY PATIENTS WITH DE NOVO OR SECONDARY AML HAVE COMPARABLE OUTCOMES AFTER INTENSIVE TREATMENTS INCLUDING HIGH DOSE (HD) CYTARABINE AND AUTOLOGOUS (AUTO) OR ALLOGENEIC (ALLO) TRANSPLANTATION (SCT)

Bernardi, M.S.; Carrabba, M.G.; Pavesi, F.; More

HemaSphere. 3(S1):480, June 2019.

Author:
Vainchenker, W.

PS1498 INCREASED RHOA ACTIVITY DUE TO A DISRUPTED FILAMIN A/ALPHAIIBBETA3 INTERACTION INDUCES MACROTHROMBOCYTOPENIA

Donada, A.; Balayn, N.; Sliwa, D.; More

HemaSphere. 3(S1):690, June 2019.

Author:
Vajia, P.

PF537 THE STAT SIGNALING BIOSIGNATURE OF CD4+ T CELL SUBSETS REFLECT THE IMMUNOGENICITY OF HIGH-RISK MDS AND PREDICT AZACYTIDINE TREATMENT OUTCOME

Lamprianidou, E.; Kordella, C.; Zoulia, E.; More

HemaSphere. 3(S1):221-222, June 2019.

Author:
Vakrmanova, B.

PF176 MONOCYTIC SWITCH AND DISCREPANCY BETWEEN FLOW CYTOMETRIC AND MOLECULAR MINIMAL RESIDUAL DISEASE ARE FREQUENT IN DUX4 REARRANGED AND PAX5-P80R MUTATED B-CELL PRECURSOR ACUTE LYMPHOBLASTIC LEUKEMIA

Novakova, M.; Vakrmanova, B.; Slamova, L.; More

HemaSphere. 3(S1):40-41, June 2019.

Author:
Valcárcel, D.

PF339 BIOLOGICAL AND CLINICAL FACTORS THAT FAVOR THE USE OF A SPECIFIC TPO-RA IN ITP PATIENTS. RESULTS FROM A SPANISH MULTICENTER STUDY

Lozano, M.L.; Mingot, M.E.; Perera, M.; More

HemaSphere. 3(S1):121-122, June 2019.

PF541 TRANSCRIPTIONAL ALTERATIONS OF HEMATOPOIETIC STEM CELLS IN MYELODYSPLASTIC SYNDROMES

Ezponda, T.; Romero, J.P.; Ainciburu, M.; More

HemaSphere. 3(S1):223, June 2019.

PF690 PREDICTORS OF THERAPY FREE RESPONSES IN ITP PATIENTS RECEIVING TPO-RA. RESULTS FROM A SPANISH MULTICENTER STUDY

Lozano, M.L.; Mingot, M.E.; Perera, M.; More

HemaSphere. 3(S1):299, June 2019.

PS1580 PREVALENCE AND RISK FACTORS FOR THROMBOSIS IN ADULT ITP PATIENTS TREATED WITH TPO-RA

Lozano, M.L.; Mingot, M.E.; Perera, M.; More

HemaSphere. 3(S1):728, June 2019.

PF583 COMPREHENSIVE ANALYSIS OF THE COMPLEXITY AND HETEROGENEITY OF THE LNCRNAS TRANSCRIPTOME IN MULTIPLE MYELOMA

Carrasco-Leon, A.; Ezponda, T.; Meydan, C.; More

HemaSphere. 3(S1):243, June 2019.

Author:
Valchuk, M.
Author:
Valencia, J.
Author:
Valent, E.
Author:
Valent, P.

S113 GENETICS AND MODELING OF HUMAN ACUTE ERYTHROID LEUKEMIA

Fagnan, A.; Riera Piqué Borràs, M.; Ignacimouttou, C.; More

HemaSphere. 3(S1):8-9, June 2019.

S840 IMPACT OF 1ST LINE TREATMENT ON OVERALL SURVIVAL IN 1.633 PATIENTS WITH CHRONIC MYELOMONOCYTIC LEUKEMIA – A MULTINATIONAL COLLABORATIVE EFFORT COORDINATED BY THE AGMT STUDY GROUP

Pleyer, L.; Leisch, M.; Kouraklis, A.; More

HemaSphere. 3(S1):374-375, June 2019.

S888 TNF-ALPHA PROMOTES CLONAL EXPANSION OF KIT D816V+ CELLS IN SYSTEMIC MASTOCYTOSIS

Greiner, G.; Witzeneder, N.; Klein, K.; More

HemaSphere. 3(S1):399-400, June 2019.

PS1331 MYELOMONOCYTIC SKEWING IN CHRONIC MYELOMONOCYTIC LEUKEMIA: PHENOTYPIC, GENOTYPIC AND BIOLOGIC FEATURES AND IMPACT ON SURVIVAL

Geissler, K.; Jäger, E.; Barna, A.; More

HemaSphere. 3(S1):607-608, June 2019.

PS1437 SETD2 NON-GENOMIC LOSS OF FUNCTION IN ADVANCED SYSTEMIC MASTOCYTOSIS (SM): PATHOGENETIC AND THERAPEUTIC IMPLICATIONS

Mancini, M.; Monaldi, C.; De Santis, S.; More

HemaSphere. 3(S1):662-663, June 2019.

S1611 MARS: MUTATION-ADJUSTED RISK SCORE FOR ADVANCED SYSTEMIC MASTOCYTOSIS

Jawhar, M.; Schwaab, J.; Álvarez-Twose, I.; More

HemaSphere. 3(S1):742-743, June 2019.

Author:
Valeri, A.

PS1209 NKG2D AND BCMA-CAR NK CELLS EFFICIENTLY ELIMINATE MULTIPLE MYELOMA CELLS. A COMPREHENSIVE COMPARISON BETWEEN TWO CLINICALLY RELEVANT CARS

Maroto-Martín, E.; Encinas, J.; García-Ortiz, A.; More

HemaSphere. 3(S1):550-551, June 2019.

Author:
Valeri, F.

PF695 ELTROMBOPAG AS SECOND LINE THERAPY IN ADULT PATIENTS WITH PRIMARY IMMUNE THROMBOCYTOPENIA (ITP) IN ATTEMPT TO TREATMENT-FREE REMISSION. UPDATED RESULTS OF A PHASE II PROSPECTIVE STUDY BY GIMEMA GROUP

Lucchini, E.; Palandri, F.; Volpetti, S.; More

HemaSphere. 3(S1):302, June 2019.

Author:
Valerianova, M.
Author:
Valganon, M.

S1612 MOLECULAR MRD STATUS AND OUTCOME AFTER TRANSPLANTATION IN NPM1 MUTATED AML: RESULTS FROM THE UK NCRI AML17 STUDY

Dillon, R.; Hills, R.; Freeman, S.; More

HemaSphere. 3(S1):743, June 2019.

Author:
Valimberti, I.
Author:
Valjalo, R.
Author:
Valk, P.

PS1003 HARMONY ALLIANCE: EUROPEAN PUBLIC-PRIVATE DATA COLLECTION LEADS THE WAY - FIRST RESULTS OF THE “PROOF-OF-PRINCIPLE” STUDY IN ACUTE MYELOID LEUKEMIA

Bullinger, L.; Valk, P.; Versluis, J.; More

HemaSphere. 3(S1):451, June 2019.

Author:
Valk, P.J.

PF262 COMPREHENSIVE DIAGNOSTICS OF ACUTE MYELOID LEUKEMIA BY WHOLE TRANSCRIPTOME RNA SEQUENCING

Griffioen, M.; Arindrarto, W.; Borràs, D.M.; More

HemaSphere. 3(S1):83, June 2019.

Author:
Valkovic, T.

PB2327 SUBSTITUTING CARMUSTINE WITH BENDAMUSTINE IN BEAM RESULTS IN DELAYED PLATELET RECOVERY AND LESS MUCOSITIS WITH SIMILAR EFFICACY – A MATCHED PAIR ANALYSIS

Aurer, I.; Zekanovic, I.; Durakovic, N.; More

HemaSphere. 3(S1):1037, June 2019.

PF182 CLINICOBIOLOGIC CHARACTERISTICS AND OUTCOME OF ELDERLY FRAIL PATIENTS WITH ACUTE LYMPHOBLASTIC LEUKEMIA INCLUDED IN A SPECIFIC PROTOCOL (ALL-07FRAIL)

Ribera, J.M.; García-Calduch, O.; Gil, C.; More

HemaSphere. 3(S1):43, June 2019.

Author:
Vallance, G.
Author:
Vallansot, R.

PS1171 TELOMERE LENGTH AT DIAGNOSIS OF CHRONIC MYELOID LEUKEMIA PREDICTS THE ACHIEVEMENT OF DEEP MOLECULAR RESPONSE TO IMATINIB

Estrada, N.; Xicoy, B.; García, O.; More

HemaSphere. 3(S1):532-533, June 2019.

PS1186 CURRENT DOSE RECOMMENDATIONS FOR PONATINIB IN CHRONIC MYELOID LEUKEMIA PATIENTS CAN DIMINISH ADVERSE EVENTS WHILE MAINTAINING EFFICACY

Garcia-Gutierrez, V.; Hernandez-Boluda, J.C.; Moiraghi, B.; More

HemaSphere. 3(S1):540-541, June 2019.

Author:
Valle, S.

PB2120 THE IMPACT OF DEPTH OF RESPONSE BEFORE AND AFTER AUTOLOGOUS STEM CELL TRANSPLANT FOR MULTIPLE MYELOMA PATIENTS

Durão, S.; Vieira, J.; Velosa, F.; More

HemaSphere. 3(S1):954-955, June 2019.

Author:
Vallejo, A.
Author:
Vallejo, M.

S1640 POLYMORPHISMS IN CYTOKINES, CHEMOKINES AND THEIR RECEPTORS GENES CONTRIBUTED TO CYTOMEGALOVIRUS REACTIVATION AFTER ALLOGENEIC STEM CELL TRANSPLANTATION

Vallejo, M.; Muñiz, P.; Carbonell, D.; More

HemaSphere. 3(S1):758-759, June 2019.

Author:
Vallerini, D.

PS1274 EPIDEMIOLOGY AND MANAGEMENT OF LATENT TUBERCULOSIS INFECTION IN ADULT PATIENTS WITH ACUTE LEUKEMIA OR APLASTIC ANEMIA: A RETROSPECTIVE MONOCENTER STUDY

Bettelli, F.; Giusti, D.; Morselli, M.; More

HemaSphere. 3(S1):583, June 2019.

Author:
Vallone, A.
Author:
Valls, J.

PS994 OLIGOMONOCYTIC CHRONIC MYELOMONOCYTIC LEUKEMIA (O-CMML) SHARES IMMUNOPHENOTYPIC AND MOLECULAR CHARACTERISTICS WITH CHRONIC MYELOMONOCYTIC LEUKEMIA (CMML)

Calvo, X.; Párraga, I.; Ferrer, A.; More

HemaSphere. 3(S1):447, June 2019.

PS1031 DECITABINE VERSUS INTENSIVE CHEMOTHERAPY IN ELDERLY UNTREATED ACUTE MYELOID LEUKEMIA

De La Fuente, A.; Tormo, M.; Beneit, P.; More

HemaSphere. 3(S1):465-466, June 2019.

Author:
Valvano, M.R.

PB1901 IBRUTINIB, SINGLE AGENT BTK INHIBITOR, FOR RELAPSED/REFRACTORY (R/R) CHRONIC LYMPHOCYTIC LEUKEMIA: A REAL-WORLD EXPERIENCE FROM RETE EMATOLOGICA PUGLIESE (REP).

Scalzulli, P.R.; Guarini, A.; Loseto, G.; More

HemaSphere. 3(S1):866-867, June 2019.

Author:
van Alphen, F.
Author:
van Beers, E.
Author:
Van Belle, S.
Author:
van Bergen, C.

PF262 COMPREHENSIVE DIAGNOSTICS OF ACUTE MYELOID LEUKEMIA BY WHOLE TRANSCRIPTOME RNA SEQUENCING

Griffioen, M.; Arindrarto, W.; Borràs, D.M.; More

HemaSphere. 3(S1):83, June 2019.

Author:
van Bergen, M.
Author:
van Bladel, D.

PF512 NEXT-GENERATION SEQUENCING-BASED CLONALITY ASSESSMENT OF IMMUNOGLOBULIN GENE REARRANGEMENTS DISTINGUISHES RELAPSE FROM SECOND PRIMARY CLASSICAL HODGKIN LYMPHOMA

van Bladel, D.; van den Brand, M.; Rijntjes, J.; More

HemaSphere. 3(S1):209, June 2019.

Author:
Van Bogaert, C.
Author:
van Bruggen, J.
Author:
Van Damme, A.

PF204 TARP AS IMMUNOTHERAPEUTIC TARGET IN AML EXPRESSED IN THE LSC COMPARTMENT

Depreter, B.; Weening, K.; Vandepoele, K.; More

HemaSphere. 3(S1):54, June 2019.

Author:
van de Donk, N.

PB2117 POMALIDOMIDE PLUS LOW-DEXAMETHASONE TREATMENT FOR ≥ 1 YEAR IN PATIENTS WITH RELAPSED REFRACTORY MULTIPLE MYELOMA AND RENAL IMPAIRMENT: A SUBANALYSIS OF THE MM-013 PHASE 2 STUDY

Weisel, K.; Dimopoulos, M.; Cook, M.; More

HemaSphere. 3(S1):953, June 2019.

S145 PHASE 3 RANDOMIZED STUDY OF DARATUMUMAB + BORTEZOMIB/THALIDOMIDE/DEXAMETHASONE (D-VTD) VERSUS VTD IN TRANSPLANT-ELIGIBLE NEWLY DIAGNOSED MULTIPLE MYELOMA: PART 1 CASSIOPEIA RESULTS

Moreau, P.; Attal, M.; Hulin, C.; More

HemaSphere. 3(S1):24-25, June 2019.